A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study of Ad2/Hypoxia Inducible Factor (HIF)-1alfa/VP16 Administered by Intramuscular Injection to Patients with No or Poor Option Chronic Critical Limb Ischemia
Latest Information Update: 30 Jul 2020
At a glance
- Drugs HIF-1 gene therapy (Primary)
- Indications Chronic limb-threatening ischemia; Peripheral arterial disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genzyme Europe
- 30 Jul 2020 New trial record